As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

In last week’s issue of The Cancer Letter, the cover story featured something special: The first de novo book published by The Cancer History Project. The book, “Backwater to Blockbuster: St. Jude Children’s Research Hospital,” co-written by Charles J. Sherr and William E. Evans, chronicles the previously untold story of St. Jude Children’s Research Hospital and its rise to becoming a global leader in pediatric cancer research.

May 20, 2026

Clinical

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

In a recent set of regulatory decisions that culminated in the resignation of FDA Commissioner Marty Makary on May 12, the agency appears to have reversed its hard-ball stance on flavored e-cigarettes.

After a year-long reign over tumult at FDA, Makary heads for the exit
Fruit-flavored e-cigs were the final blow for the commissioner

The immediate impetus for FDA Commissioner Marty Makary’s exit from the top job at FDA is arguably less significant than the legacy of dysfunction he leaves behind.

May 15, 2026

Vol.52 No.19

By Claire Marie Porter

In Brief

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials

The Mount Sinai Tisch Cancer Center has entered a partnership with Cancer Hope Network to launch Peer Access to Trials, Hope and Support, a peer-to-peer program that gives patients and caregivers access to one-on-one peer mentorship from trained volunteers who have faced cancer themselves, either as survivors or caregivers.

May 15, 2026

Vol.52 No.19

In Brief

LSU LCMC Health cancer center strengthens cancer clinical trials infrastructure to expand access across Louisiana

The LSU LCMC Health Cancer Center expanded its Cancer Clinical Trials Office.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

FDA approved an oral combination of Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older or who are ineligible for intensive induction chemotherapy.

May 15, 2026

Vol.52 No.19

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

YOU MAY BE INTERESTED IN

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

After a year-long reign over tumult at FDA, Makary heads for the exit
Fruit-flavored e-cigs were the final blow for the commissioner

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials

LSU LCMC Health cancer center strengthens cancer clinical trials infrastructure to expand access across Louisiana

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

Renew today!

Subscriber content

Never miss an issue!

Login

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

YOU MAY BE INTERESTED IN

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applicationsCritics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

After a year-long reign over tumult at FDA, Makary heads for the exitFruit-flavored e-cigs were the final blow for the commissioner

Mount Sinai and Cancer Hope Network launch peer support program to help patients navigate treatment, survivorship, and clinical trials

LSU LCMC Health cancer center strengthens cancer clinical trials infrastructure to expand access across Louisiana

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

Never miss an issue!

Login

FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market

After a year-long reign over tumult at FDA, Makary heads for the exit
Fruit-flavored e-cigs were the final blow for the commissioner